Chemotherapy-induced nausea and vomiting: State of the art in 2006

Journal of Supportive Oncology

Volumn 4, Issue 2 SUPPL. 1, 2006, Pages 3-8

  Schwartzberg, Lee S ^a,b,c  

^a WEST CLINIC   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c CARES (Cancer Assessment Risk Evaluation and Surveillance) Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CETUXIMAB; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOLASETRON MESILATE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANISETRON; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NEUROKININ 1 RECEPTOR; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PROCHLORPERAZINE; UNINDEXED DRUG;

ANTIEMETIC ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RESPONSE; FOLLOW UP; HUMAN; NAUSEA AND VOMITING; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMANS; ISOQUINOLINES; MEDICAL ONCOLOGY; MORPHOLINES; NAUSEA; NEOPLASMS; QUALITY OF LIFE; QUINUCLIDINES; VOMITING;

EID: 33644747457     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. American Society of Health-System Pharmacists. ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm 1999;56:729-764.
2. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 2005;13:80-84.
3. Balfour JA, Goa KL. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs 1997:54:273-298.
4. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-28.
5. National Comprehensive Cancer Network. Antiemesis: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2004;2:470-490.
6. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004:100:2261-2268.
7. DeMoor C, Cohen L, Eisenberg PD, et al. Oncologists' compliance with antiemetic guidelines (AEG) and outcomes of patients (pts) receiving emetogenic chemotherapy (CT). Presented at the 39th Annual Meeting of the American Society of Clinical Oncology. Chicago, Ill. May 31-June 3, 2003. Abstract 2924.
8. Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003;97:2880-2886.
9. 3 receptor antagonist: results of a phase III, single-dose trial vs dolasetron. Cancer 2003;98:2473-2482.
10. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577.
11. Rubenstein EB, Gralla RJ, Eisenberg P, et al. Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase III trials. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology. Chicago, Ill. May 31-June 3, 2003. Abstract 2932.
12. Hajdenberg J, Grote T, Yee L, et al. Palonosetron plus dexamethasone is safe and effective when co-administered as an infusion in patients receiving moderately emetogenic chemotherapy: results of an open-label, pilot study. Support Care Cancer 2005;13:417 [abstract 04-027].
13. Grunberg SM, Vanden Burgt JA, Berry S, et al. Prevention of delayed nausea and vomiting (D-CINV): carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO). Presented at the 40th Annual Meeting of the American Society of Clinical Oncology. New Orleans, La. June 5-8, 2004. Abstract 8051.
14. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-2830. Erratum in: J Clin Oncol 2005;23:5851 (dosage error in abstract).
15. Hickok JT, Roscoe JA, Morrow GR, et al. 5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005;6:765-772. Published online September 13, 2005.
16. Grote T, Hajdenberg J, Cartmell A, et al. Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy (CT). Presented at the 40th Annual Meeting of the American Society of Clinical Oncology. New Orleans, La. June 5-8, 2004. Abstract 8262.